

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*Innovation . Verification . Development*

**IVD Medical Holding Limited**

**華檢醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1931)**

## **VOLUNTARY ANNOUNCEMENT**

### **COMPLETION OF THE FIRST RESERVE OF ETHEREUM (“ETH”)**

This announcement is made by IVD Medical Holding Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the latest information on business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, to facilitate the rapid implementation of the Group’s “Global Enhanced ETH Vault” strategy, the Company will utilize up to HK\$880 million to purchase ETH as reserve assets in the open market, upon the approval of the Board. The Company will increase the purchase amount through its own funds and proceeds raised from fundraising activities. Further announcements will be made in accordance with the Listing Rules, including but not limited to convening a general meeting to approve the increase in the purchase amount. The Company has completed the compliant purchase of its first batch of ETH through HashKey Exchange, a licensed virtual asset exchange in Hong Kong. The Company plans to continue increasing its holdings through a regular investment strategy, with the goal of becoming a leading listed company in the Hong Kong stock market and globally in terms of its ETH reserves.

As of the date of this announcement, the Company has purchased a total of 5,190 ETH in the first batch, each at an average price of HK\$28,798.21 (equivalent to US\$3,661), with a total transaction value of HK\$149.47 million. The first batch of ETH purchases was completed in the open market through HashKey Exchange, funded by the Group’s existing cash reserves.

## STRATEGIC BACKGROUND AND NECESSITY

### 1. Core Objectives of Strategic Upgrading

With reference to the Group's new announcement on 8 August 2025, in relation to establishing a global enhanced ETH vault, upgrading the Company's global strategy, and creating value for ecosystem participants, the Company has officially launched its strategic upgrade. With the "Global Enhanced ETH Vault" as its core hub, the Company aims to build a value bridge between the healthcare industry and the Web3 ecosystem through the tokenization of innovative healthcare drug assets (real-world assets ("RWA(s)")) and on-chain financial innovation.

This ETH purchase is a key step in the implementation of the strategy, aiming to:

- Strengthen underlying reserves: ETH, as a core asset in smart contract platforms and the decentralized finance ("DeFi") ecosystem, provides liquidity support and value anchoring for the Group's RWAs;
- Connect with global capital: By compliantly holding ETH, the Company aims to attract traditional institutional investors to participate in on-chain financing for innovative healthcare drugs;
- Enhance risk resilience: Establish a two-track strategy of "ETH Reserve Vault + ETH Creation Engine", to balance downside protection with upside resilience.

### 2. Selecting the Compliance Support of HashKey Exchange

This transaction was executed through HashKey Exchange, a licensed exchange under HashKey Group. This platform holds a Type 1 (Securities Trading) and Type 7 (Provision of Automated Trading Services) license issued by the Hong Kong Securities and Futures Commission (SFC), and has been approved to expand its license scope to the retail business sector. It also holds a Trust or Company Service Provider (TCSP) license issued by the Hong Kong Companies Registry (Certificate No. TC006486), and is legally qualified to engage in virtual asset custody services.

In terms of asset security structure, HashKey Exchange has established a complete segregation mechanism between customer funds and operational capital, with funds held in separate accounts and protected by institutional-grade insurance. It has also obtained two certifications: the ISO 27001 Information Security Management System and the ISO 27701 Data Privacy Protection System, thereby establishing a comprehensive risk control system across the entire lifecycle. Based on these compliance qualifications and security structure, HashKey Exchange can legally and compliantly fulfill its virtual asset custody functions for users, ensuring transaction transparency and asset security.

Previously, the Group has signed a "Global Strategic Cooperation Framework Agreement" with HashKey Group (see the second announcement released on 8 August 2025 for details). The two parties will expand their collaboration in areas such as ETH block trading, RWA tokenization and global liquidity management.

## **REGULAR INVESTMENT STRATEGY AND FUTURE PLANS**

In accordance with the Group's "Global Enhanced ETH Vault" strategy, the Company will adopt a regular investment strategy to continuously increase its holdings of ETH. This strategy aims to smooth market volatility risks, optimize investment costs and gradually expand the Group's ETH reserves through regular and quantitative purchases.

In the future, the Company plans to continue increasing its ETH holdings through a variety of methods, including purchasing coins with its own funds, upgrading its own assets and increasing holdings through ATM financing, based on market conditions and the Company's financial status. Combining the Group's dual-track strategies of "ETH Reserve Vault" and "ETH Creation Engine", the goal is to ensure that the Group's ETH reserve scale and the ETH concentration per share are in a leading position in the Hong Kong stock market and even globally.

## **IMPACT AND SIGNIFICANCE OF THE TRANSACTION ON THE GROUP**

- Accelerated strategic implementation: Rapidly building ETH reserves through compliant channels will provide underlying liquidity support for the issuance of healthcare RWAs;
- Improved capital efficiency: ETH, as an on-chain fuel, can reduce costs in cross-border payments, smart contract execution and other processes;
- Industry benchmark effect: Becoming one of the first healthcare innovation companies in the Hong Kong stock market to systematically reserve ETH, leading the trend of integrating traditional industries with Web3;
- Investor value extension: Providing shareholders with a compliant channel to access crypto asset dividends, while sharing in the benefits of the Web3 ecosystem's development through the appreciation of ETH.

The Board believes that this ETH purchase is consistent with the Group's long-term strategy of "Global Enhanced ETH Vault". Building core reserve assets through compliant channels will help improve capital efficiency, reduce systemic risk and provide critical infrastructure support for the tokenization of medical innovative drug assets (RWAs). The Board expresses full confidence in HashKey Group's expertise and the prospects of the strategic collaboration between the two parties.

The Board hereby emphasizes that the cryptocurrency market is highly volatile, and the price of ETH may fluctuate significantly due to factors such as macroeconomic and regulatory changes. Therefore, shareholders and potential investors are advised to exercise caution when trading the Company's securities and make their own assessment of the risks.

The Group will disclose the size of its ETH holdings, the implementation of its fixed investment plan and the progress of its medical RWA issuance in a timely manner based on the pace of strategic advancement to ensure that investors fully understand the strategic value.

By Order of the Board  
**IVD Medical Holding Limited**  
**Lin Xianya**  
*Executive Director*

Hong Kong, 8 August 2025

*As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.*

*This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements are not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.*

*If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.*